6CM
SPRY icon

683 Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

683 Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,500
Closed -$140K – 240
2023
Q1 		$140K Sell
21,500
-4,554
-17% -$35K 0.01% 213
2022
Q4 		$222K Buy
+26,054
New +$169K 0.02% 148

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

683 Capital Management's SPRY Position: Q2 2023 in Review

683 Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 21,500 shares — an estimated $140K sold.

683 Capital Management first reported a position in SPRY in Q4 2022 and held it in 2 quarters. The position peaked at $222K in Q4 2022. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

  • 683 Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 21,500 ARS Pharmaceuticals shares in Q2 2023, an estimated $140K.
  • 683 Capital Management first reported a position in ARS Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's ARS Pharmaceuticals position peaked at $222K in Q4 2022.
  • 92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.